NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03036813,Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE),https://clinicaltrials.gov/study/NCT03036813,GBT_HOPE,COMPLETED,"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease",YES,Sickle Cell Disease,DRUG: voxelotor|OTHER: Placebo,"Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24, Number of participants with increase in Hb \>1 g/dL from Baseline to Week 24, Baseline to Week 24","Annualized Vaso-Occlusive Crisis (VOC) Incidence Rate, Number of Vaso-Occlusive Crisis (VOC) events averaged per year., Baseline to Week 72|Percentage Change From Baseline in Hemolysis Measures, Percentage change from Baseline to week 24 in unconjugated bilirubin, Baseline to Week 24|Percentage Change From Baseline in Hemolysis Measures, Percentage change from Baseline to week 24 in the absolute reticulocyte which is used to estimate the degree of effective erythropoiesis. This values is important in Sickle Cell Disease and was reported by the central laboratory., Baseline to Week 24|Percentage Change From Baseline in Hemolysis Measures, Percentage change from Baseline to week 24 in reticulocytes % which is a % of total Red Blood Cells (RBCs)., Baseline to Week 24|Percentage Change From Baseline in Hemolysis Measures, Percentage change from Baseline to week 24 in Lactate Dehydrogenase (LDH), Baseline to Week 24",,Pfizer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,449,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",GBT440-031|C5341043,2016-12,2019-10-08,2019-10-08,2017-01-30,2021-01-07,2023-07-27,"Birmingham, Alabama, 35205, United States|Mobile, Alabama, 36693, United States|Little Rock, Arkansas, 72204, United States|Oakland, California, 94609, United States|Miami, Florida, 33136, United States|Atlanta, Georgia, 30342, United States|Chicago, Illinois, 60612, United States|Indianapolis, Indiana, 46260, United States|Baton Rouge, Louisiana, 70808, United States|New Orleans, Louisiana, 70112, United States|Baltimore, Maryland, 21287, United States|Bethesda, Maryland, 20817, United States|Boston, Massachusetts, 02115, United States|Boston, Massachusetts, 02118, United States|Detroit, Michigan, 48201, United States|Newark, New Jersey, 07112, United States|Bronx, New York, 11501, United States|New York, New York, 10032, United States|Chapel Hill, North Carolina, 27514, United States|Durham, North Carolina, 27710, United States|Greenville, North Carolina, 27834, United States|Oklahoma City, Oklahoma, 73112, United States|Philadelphia, Pennsylvania, 19107, United States|Pittsburgh, Pennsylvania, 15219, United States|Charleston, South Carolina, 29425, United States|Memphis, Tennessee, 38105, United States|Nashville, Tennessee, 37232, United States|Houston, Texas, 77030, United States|Richmond, Virginia, 23298, United States|Toronto, M5G 2C4, Canada|Alexandria, 21131, Egypt|Cairo, 11566, Egypt|Cairo, Egypt|Zagazig, 44519, Egypt|Cr√©teil, 94010, France|Paris, 75743, France|Paris, 75908, France|Monza, Milano, 20900, Italy|Padova, 35128, Italy|Verona, 37134, Italy|Kingston, JMAAW15, Jamaica|Nairobi, 42325-00100, Kenya|Nairobi, 47855, Kenya|Nairobi, 59857-00200, Kenya|Siaya, 144-40600, Kenya|Beirut, 11072020, Lebanon|Beirut, 1136044, Lebanon|Tripoli, 1434, Lebanon|Amsterdam, 1105 AZ, Netherlands|Den Haag, 2545 CH, Netherlands|Rotterdam, 3015 AA, Netherlands|Muscat, 123, Oman|Adana, 01130, Turkey|Kayseri, 38039, Turkey|Mersin, 33342, Turkey|London, E11BB, United Kingdom|London, E96SR, United Kingdom|London, SE17EH, United Kingdom|London, SE59NU, United Kingdom|London, W12 0HS, United Kingdom|London, WC1N3BG, United Kingdom|Manchester, M13 9WL, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/13/NCT03036813/Prot_001.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/13/NCT03036813/SAP_000.pdf"
